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1. Introduction 
Chronic kidney disease has become an important global public health threat. There are 
currently approximately 387,000 patients with end-stage kidney disease in the United States 
and 1.8 million patients worldwide who require dialysis therapy or a transplant for survival 
(DuBose, 2007). Over 23 million children and adults have diabetes mellitus in the United 
States, representing nearly 8% of the population. Forty-three percent of end-stage kidney 
disease patients in the US have diabetes mellitus, and more than 90% of these diabetics have 
type 2 diabetes; these statistics are similar to the situation in Korea (ESRD Registry 
Committe, 2010). Type 2 diabetes mellitus, hypertension, obesity, and dyslipidemia are 
components of metabolic syndrome and are all major risk factors for cardiovascular disease. 
With the availability of excess food in many parts of the world, obesity is a growing 
problem that is increasing at an alarming rate in adults as well as in children. Obesity 
increases the risk for type 2 diabetes mellitus, cardiovascular disease, cancer, 
musculoskeletal disorders, and pulmonary disease (Kramer, 2006). Although obesity is an 
important risk factor for diabetes and hypertension, the two most common etiologies of 
chronic kidney disease, obesity itself may also potentiate kidney damage.  
The important etiologic factor of metabolic syndrome is insulin resistance, which leads to 
hyperinsulinemia; activation of the renin-angiotensin-aldosterone system (RAAS); increased 
syntheses of transforming growth factor beta 1 (TGF-1), insulin-like growth factor-1 (IGF-1) 
and connective tissue growth factor (CTGF); and collagen production in the kidney. These 
changes cause renal mesangial cell proliferation, extracellular matrix (ECM) expansion and 
renal fibrosis (Sarafidis & Ruilope, 2006). In addition to its proliferative actions in the 
kidney, insulin likely influences renal function at the tubular level because its sodium-
retaining action results in hypertension. Insulin may also contribute to glomerulus injury by 
increasing the glomerular filtration rate (GFR), intraglomerular pressure and urinary 
albumin excretion. Moreover, insulin resistance and hyperinsulinemia are directly 
associated with low endothelial nitric oxide synthesis, altered endothelin-1 secretion and 
high oxidative stress production. Although the kidney is affected by hyperglycemia in 
patients with diabetes mellitus, the role of altered renal lipid metabolism has not yet been 
extensively studied in obesity-related kidney disease, including diabetic nephropathy. 
However, previous reports have revealed that abnormalities in lipid and glucose 
metabolism in the kidney are also important in the development of organ injury, as is 
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adipose tissue (Drury et al., 1950; Rubenstein et al., 1975; Schoolwerth et al., 1988; Stumvoll 
et al., 1997).  
Obesity is a risk factor for the development of hypertensive nephrosclerosis, and focal and 
segmental glomerular sclerosis is considered to be independent risk factors for the 
progression of renal disease. Recent experimental and human clinical trials suggest that 
obesity can influence renal injury through various mechanisms, including hemodynamic 
changes in the glomeruli, alteration of renal lipid metabolism, increased oxidative stress, 
and inflammation via alteration of adipocytokines induced by adipose tissue changes in 
obesity. Additionally, circulating adipocytokines can also positively or negatively influence 
systemic insulin resistance, leading to organ injury and endothelial dysfunction. Recent 
insights about adipose tissue biology suggest that adipose tissue is not an energy storage 
tissue but an active endocrine organ that interacts with major target organs of metabolic 
syndrome, such as the liver, muscles and kidneys. A better understanding of adipose tissue 
biology will help researchers develop new therapeutic strategies for managing metabolic 
syndrome as well as diabetic vascular complications.  
2. Adipose tissue and kidney 
2.1 Adipose tissue as an endocrine organ 
During the development of obesity, multiple functional and structural changes occur in the 
adipose tissue (called “adiposopathy“), such as an increase in the number and size of 
adipocytes, an increase in the infiltration of mononuclear cells, rarefaction of blood vessels, 
and apoptosis (Wellen & Hotamisligil, 2003). Because leptin, the first identified 
adipocytokine, has a systemic effect in the body, adipose tissue is now considered to be an 
active endocrine organ (Zhang et al., 1994). While many adipocytokines have been 
proposed, few have been studied in detail, and even fewer have been investigated in the 
kidney. These adipocytokines include several active molecules released by adipocytes, such 
as leptin, resistin, adiponectin or visfatin, as well as cytokines released by inflammatory 
cells, such as tumor necrosis factor alpha (TNF-), interleukine-6 (IL-6), monocyte 
chemoattractant protein-1 (MCP-1), and interleukine-1 (IL-1). Interestingly, the circulating 
levels of these adipocytokines have been found to be altered in experimental animals and 
patients with kidney disease, which is an independent risk factor for cardiovascular 
diseases. Moreover, the production, secretion and regulatory actions of these proteins are 
not limited only to adipose tissue but are also described in other organ tissues. It is now 
recognized that the kidney itself can alter the clearance of adipocytokines as well as produce 
them. Recent experimental and clinical evidence has demonstrated possible molecules that 
cross-talk between adipose tissue and the kidney in the pathogenesis of obesity-related renal 
disease. 
2.2 Role of leptin in kidney disease 
Leptin is a representative adipocytokine that is primarily produced in adipose tissue and 
that plays an important role in appetite control and regulation of energy expenditure. The 
plasma leptin concentration is positively increased according to the degree of adiposity 
(Friedman & Halaas, 1998), and hyperleptinemia has been reported to be an independent 
risk factor for cardiovascular disease (Ren, 2004; Soderberg et al., 1999). However, recent 
experimental data imply that leptin may directly influence renal function through the small 
isoform of the leptin receptor (Ob-Ra) in the kidney (Wolf & Ziyadeh, 2006). Infusion of 
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leptin in normal rats induced glomerulosclerosis and proteinuria, and transgenic mice 
overexpressing leptin also showed increased renal expressions of fibronectin and type IV 
collagen (Wolf et al., 2002). Several in vitro experiments using glomerular endothelial and 
mesangial cells also demonstrated that leptin stimulates the proliferation of endothelial 
cells, increases glucose uptake into mesangial cells and finally increases the productions of 
TGF-β1 and collagen (Wolf et al., 1999). In addition, leptin plays an important role in the 
progression of atherosclerosis, such as platelet aggregation and thrombosis, production of 
inflammatory cytokines (including TNF- and IL-6) and calcification of vascular smooth 
muscle cells (Konstantinides et al., 2001). Leptin is also associated with sympathetic 
activation and can lead to hypertension and renal injury (Henegar et al., 2001; Kambham et 
al., 2001). Collectively, these data suggest that leptin contributes to the development of renal 
injury through both direct and indirect effects.  
2.3. Role of adiponectin in kidney disease 
Adiponectin is an important anti-diabetic adipocytokine produced in adipose tissue 
(Scherer, 2006). A large body of evidence has shown that adiponectin improves insulin 
sensitivity and exerts an anti-inflammatory effect in vascular cells (Scherer, 2006; Axelsson, 
2008; Goldstein & Scalia, 2004). Adiponectin-null mice show increased susceptibility to 
insulin resistance when fed a high-fat diet, and treatment with adiponectin improves insulin 
sensitivity (Maeda et al., 2002). Studies of the genetic modulation of adiponectin receptors 
also suggest that representative adiponectin receptors 1 and 2 are involved in insulin 
resistance through the activation of AMP-activated protein kinase (AMPK) and peroxisome 
proliferator-activated receptor (PPAR) (Kadowaki et al., 2008; Mao et al., 2006). 
Interestingly, serum levels of adiponectin are lower in obese patients compared with those 
in lean patients (Kanaya et al. 2006; Laughlin et al. 2007). Although the association between 
adiponectin level and renal disease is still controversial, recent clinical studies have reported 
that serum adiponectin and albuminuria levels were inversely correlated (Tsioufis et al., 
2005; Sharma et al., 2008; Yano et al., 2007). Considering that adiponectin is produced in 
adipose tissue and shows an inverse relationship with the amount of adiposity, these 
findings support the possibility of adiponectin as a candidate molecule that connects obesity 
and kidney disease.  
Sharma et al. first reported the link between adiponectin and albuminuria in an adiponectin-
null mouse (Sharma et al., 2008). The C57BL/6 adiponectin-null mouse exhibits albuminuria 
and pathologic changes in foot process effacement of podocytes (Sharma et al., 2008). This 
study observed that podocytes express the adiponectin R1 receptor, and that treatment with 
adiponectin normalized the albuminuria and pathologic changes of the foot process through 
adiponectin stimulation of the AMPK pathway, a key regulator of intracellular energy status 
with potent anti-proliferative and anti-oxidative effects. In addition, renoprotective effects of 
adiponectin have also been reported in the subtotal renal ablation model of adiponectin-
knockout mice (Ohashi et al., 2007). An increase in visceral fat increases the productions of 
proinflammatory adipocytokines, which leads to an increase in oxidative stress in various 
target organs. Furthermore, the increase in adipose tissue oxidative stress results in further 
aggravation of systemic oxidative stress and inflammation, which positively affect the 
development of insulin resistance. Taken together, these data suggest that adiponectin is a 
possible mechanistic link between adipose tissue and renal disease. However, it is not yet 
clear whether adiponectin receptor 2 has a role in obesity-related kidney disease.  
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2.4 Role of visfatin in kidney disease 
Among the adipocytokines, visfatin is a ubiquitous intracellular enzyme; it is also known as 
nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony-enhancing factor 
(PBEF-1). Visfatin is a newly identified adipocytokine that is secreted by adipocytes and that 
mimics insulin in animals (Fukuhara et al., 2005); however, its role in kidney disease is not 
yet known. In humans, early data have suggested that visfatin concentrations are increased 
in patients with type 2 diabetes mellitus (Chen et al., 2006), but that it is not in itself a 
mediator of insulin resistance (Lopez-Bermejo et al., 2006). Plasma visfatin concentrations 
were recently found to increase in patients with diabetes mellitus compared with those in 
healthy control participants (Kang et al., 2010c). These data did not show any significant 
relationships between plasma visfatin concentration and metabolic parameters, including 
the homeostasis model assessment of insulin resistance (HOMA-IR), HbA1c, or body-mass 
index (BMI). However, plasma levels of visfatin were markedly increased in patients with 
diabetic nephropathy irrespective of the stage of nephropathy. Visfatin level was associated 
with systemic inflammatory markers (such as MCP-1), and its levels were positively 
associated with systolic blood pressure, fasting blood glucose and carotid intima-medial 
thickness (IMT). These findings suggest that the plasma concentration of visfatin is elevated 
when inflammatory conditions exist.  
Another experiment reported that plasma concentration of visfatin was increased in animals 
as well as humans during the early stages of diabetic nephropathy in type 2 diabetics (Kang 
et al., 2010d). The present study found that visfatin expression was markedly up-regulated 
in both the glomeruli and proximal tubules of the diabetic kidney. In another experiment, 
the synthesis and physiological action of visfatin in renal cells (such as mesangial cells) were 
studied to investigate the role of visfatin in diabetic nephropathy (Song et al., 2008). Visfatin 
was found to be synthesized in renal mesangial cells as well as adipocytes and stimulated 
glucose uptake in glomerular mesangial cells mediated by glucose transporter-1 (GLUT-1). 
In glomerular podocytes and tubular cells as well as mesangial cells, high glucose 
stimulation up-regulated marked visfatin synthesis but did not increase the response to 
angiotensin II stimulation (Kang et al., 2010d; Song et al., 2008). Exogenous visfatin 
administration induced synthesis of pro-fibrotic molecules, including TGF-β1, PAI-1 and 
type I collagen. Endogenous visfatin produced from renal cells, such as mesangial cells, 
podocytes and tubular cells, seems to stimulate glucose uptake and intracellular metabolic 
abnormalities.  
Hyperglycemia in diabetes is associated with increased glucose uptake into cells and causes 
intracellular metabolic alterations, which are considered an important pathogenesis for 
diabetic microvascular complications. Consistently, previous studies have suggested that 
glucose uptake into mesangial cells promotes mesangial extracellular matrix protein 
accumulation, which is characteristic of diabetic nephropathy (Ayo et al., 1991; Haneda et 
al., 1991; Heilig et al., 1995).  
However, in diabetic animals, exogenous visfatin administration interestingly improved 
diabetic nephropathy (Song et al., 2008). These results were in opposition to previously 
obtained observational data of humans and animals. First, visfatin treatment improved 
urinary albumin excretion in diabetic animals irrespective of plasma glucose concentration. 
Second, dramatic improvements in plasma lipid concentration and insulin resistance were 
observed. Third, visfatin regulated the balance of lipid metabolism in the diabetic kidney as 
well as in the liver and adipose tissue. Several possibilities may explain these paradoxical 
results. Visfatin may have a compensatory effect via both the autocrine and paracrine 
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pathways, resulting in improved insulin resistance and lipid metabolism. Long-term visfatin 
infusion may restore the decreased availability of insulin receptors in the kidney. The next 
possibility is the benefit of a more physiologic route of intra-peritoneal visfatin injection 
compared to vascular infusion, which directly accumulates in the liver and visceral adipose 
tissue (the main organs regulating lipid and glucose metabolism) before achieving adequate 
concentration levels in the systemic circulations of the plasma, heart and kidney. Therefore, 
the secondary beneficial effects (improving insulin resistance and dyslipidemia) of visfatin 
on the kidney may be more effective than the direct renal effects. However, it is equally 
possible that a difference in the models of insulin resistance may have accounted for this 
apparent discrepancy. Despite the paradoxical effect of visfatin in this study, visfatin was 
shown to have beneficial effects on lipid metabolism and insulin resistance in diabetic 
animal experiments (Song et al., 2008). Long-term therapy with intraperitoneal visfatin 
injection eventually induced various organ-protective effects in type 2 diabetic nephropathy. 
Based on these results, visfatin might play some crucial role in the pathogenesis of insulin 
resistance and diabetic nephropathy. 
2.5 Role of Renin-Angiotensin-Aldosterone System (RAAS) 
Several clinical trials of hypertension have demonstrated a lower incidence of diabetes 
mellitus among patients treated with renin-angiotensin-aldosterone system (RAAS) 
inhibitor compared to that of those given other classes of anti-hypertensive drugs (Dahlof et 
al., 2002; Hansson et al., 1999; Yusuf et al., 2000). Although these studies were mostly 
performed among patients with hypertension or congestive heart failure, a relative risk for 
new-onset diabetes mellitus was reduced in patients using RAAS in a meta-analysis of 
randomized controlled trials. Furthermore, the activity of RAAS is also associated with 
metabolic syndrome (Engeli, 2006). These findings suggest that RAAS may have an 
important role in the development of diabetes mellitus. Interestingly, mature adipocytes 
express all components of RAAS, including angiotensinogen, angiotensin-converting 
enzyme and angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptors (Engeli et al., 
2000). For these reasons, the anti-diabetic effect of RAAS inhibition was recently evaluated, 
and the effects of these drugs on adipocyte function were observed to occur via the 
modulation of adipocytokines (Kang et al., 2010a; Lee et al., 2008). Administration of an AT 
receptor antagonist (ARB) improved insulin resistance simultaneous to an improvement in 
diabetic nephropathy in an animal experiment. ARB augmented lipid accumulation, 
differentiation of adipocytes and improvement in adipocytokine synthesis in type 2 diabetic 
animals. In animals with diabetic nephropathy, ARB improved alterations in renal lipid 
metabolism and subsequently reduced renal cholesterol and triglyceride contents with 
decreased albuminuria. Importantly, in both adipocytes and renal cells, AT2 increased the 
synthesis of pro-inflammatory molecules in adipose tissue, such as plasminogen activator 
inhibitor-1 (PAI-1), MCP-1, and nuclear factor kappa B (NF-B) activation, and then their 
synthesis was suppressed by ARB treatment.  
The mechanisms linking obesity to hypertension are important for identifying specific 
treatments for these patients, and some evidence suggests that obesity is associated with 
increased aldosterone levels. Obesity induces activation of the RAS system in adipose tissue, 
and weight reduction often restores RAS activity to basal levels in lean healthy participants 
(Engeli et al., 2005). Proposed mechanisms for these interesting findings are the role of 
adipose-tissue-derived products called mineralocorticoid stimulating factor (MSF) and free 
fatty acids. An in vitro experiment showed the presence of MSF in conditioned media of 
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adipocytes, which increased the production of aldosterone in cultured adrenal gland cells. 
Increased fatty acid production (especially non-esterified fatty acids) from adipose tissue in 
obese patients might stimulate aldosterone production in the adrenal gland. Metabolic 
syndrome and the cardiovascular and renal abnormalities associated with insulin resistance 
are mediated in part by aldosterone activity on the mineralocorticoid receptor (MR). In 
addition, recent research has shown that aldosterone promotes adipocyte differentiation in 
vitro through specific activation of the MR; a pro-inflammatory role for MR activation in 
adipose tissue has also been reported (Hirata et al., 2009). Patients with primary 
hyperaldosteronism (PA) showed differences in glucose metabolism compared with that of 
essential hypertensive patients; patients with PA have a lower beta-cell function that is 
influenced by aldosterone levels. This association was initially described in individuals with 
primary hyperaldosteronism and impaired glucose tolerance (Conn, 1965). Increased plasma 
aldosterone levels are associated with insulin resistance. It is also of interest that plasma 
aldosterone levels appeared to be positively correlated with plasma glucose levels in 
diabetic rat models of our previous study (Han et al., 2006). Aldosterone impairs lipid 
metabolism and insulin signaling in cardiovascular and renal tissue, as well as in fat, 
skeletal muscle and the liver (Sowers et al., 2009). Since aldosterone is also associated with 
glucose metabolism and dyslipidemia, selective aldosterone blockade may represent a 
particularly attractive therapeutic strategy in obese patients who have a cluster of 
cardiovascular risk factors. 
Recently, a new RAAS inhibitor, direct renin inhibitor (DRI), has been used to manage 
hypertensive patients. While DRI has been primarily been studied in diabetic nephropathy, 
its effects have been extended into insulin resistance and metabolic syndrome in animal 
experiments (Kang et al., 2010a). DRI, which is independent of blood pressure lowering 
effects, showed a beneficial influence on the diabetic vascular complications of renal and 
cardiac injury. More importantly, its direct effect on pro-inflammatory molecules, such as 
MCP-1, TGF-1, type Ⅳ collagen, PAI-1, and vascular endothelial growth factor (VEGF), 
may occur in the presence of target organ injury and not via RAAS activation. Additional 
findings have also revealed that DRI improved lipid parameters and insulin resistance with 
no effect on blood glucose level in the modulation of lipid metabolism in adipose, hepatic 
and renal tissues. Therefore, the RAAS inhibitor improved insulin resistance and lipid 
metabolism via anti-inflammatory actions on adipose tissue and also improved diabetic 
nephropathy. 
2.6 Role of the MCP-1/CCR2 pathway 
The kidney has been regarded as a target organ of critical complications in patients with 
metabolic syndrome, obesity, hypertension, dyslipidemia, and type 2 diabetes mellitus. 
While its important role in altering energy and glucose metabolism has been reported in 
patients with chronic kidney disease (Rubenstein et al., 1975), there is also considerable 
evidence of renal glucose production and utilization in animal models (Drury et al., 1950; 
Mather and Pollock, 2011; Schoolwerth et al., 1988; Stumvoll et al., 1997). The kidney 
contributes to glucose homeostasis through gluconeogenesis, glucose filtration, glucose 
reabsorption, and glucose consumption (Gerich, 2010). The human liver and kidneys release 
approximately equal amounts of glucose via gluconeogenesis in the post-absorptive state. 
Traditionally, pharmacotherapeutic interventions have been aimed at stimulating insulin 
secretion or addressing peripheral insulin resistance. A novel drug class currently being 
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studied targets another pathophysiological process in the kidney of type 2 diabetes mellitus 
(Mather & Pollock, 2010; Neumiller et al., 2010). Therefore, the development of glucose-
lowering drugs involving inhibition of renal glucose reabsorption, such as the sodium-
glucose co-transporter 2 (SGLT2) inhibitor, has recently begun for use in type 2 diabetes 
mellitus. 
The pathophysiology of diabetic nephropathy is multifactorial; it involves metabolic factors 
including hyperglycemia, genetic factors and hemodynamic factors such as hypertension 
and glomerular hyperfiltration (Han et al., 2006; Kang & Cha, 2009; Kang et al., 2009). 
Diabetic nephropathy was initially considered a non-inflammatory glomerular disease, and 
the inflammatory process has been largely ignored as a mechanism of diabetic nephropathy. 
However, recent animal and human clinical studies have provided evidence of the 
important role of inflammation in the development and progression of diabetic 
nephropathy (Han et al., 2010; Han et al., 2006; Ko et al., 2008). Hyperglycemia induces 
monocyte/macrophage infiltration in the kidney and contributes to the deposition of 
fibrotic molecules, which can lead to glomerulosclerosis. Moreover, there is abundant 
experimental evidence that inhibiting macrophage recruitment or macrophage activation 
can ameliorate renal inflammation and fibrosis. The MCP-1/C-C chemokine receptor 2 
(CCR2) pathway has been reported to be an important mediator for inflammatory 
glomerular disease. The act of MCP-1 binding to the CCR2 receptor induces infiltration of 
inflammatory cells and proliferation of resident glomerular cells, such as epithelial and 
endothelial cells (Kato et al., 1999; Viedt et al., 2002). In addition, glomerular podocytes are 
the major glomerular cells that express MCP-1 in various proteinuric conditions, including 
diabetic and membranous nephropathies (Hartner et al., 2005; Prodjosudjadi et al., 1995). 
Blockade or loss of MCP-1 has been shown to provide renoprotective effects in experimental 
diabetic nephropathy (Chow et al., 2006; Kanamori et al., 2007), which suggests an 
influential role of the MCP-1/CCR2 pathway for the inflammatory process in diabetic 
injury. In addition, urinary MCP-1 excretion is increased in patients with early diabetic 
nephropathy, and acute-phase markers of inflammation are associated with the 
nephropathic state in type 2 diabetic patients (Dalla Vestra et al., 2005; Wada et al., 2000). 
However, CCR2, a seven-transmembrane protein-coupled receptor, is a receptor for MCP-1 
and is expressed by monocytes. Local recruitment of monocytes is considered to be the 
predominant mechanism by which MCP-1 contributes to renal damage.  
Many tissues, such as the pancreas, liver, skeletal muscle, heart, and vessels, are adversely 
affected by obesity (Matsuzawa, 2006). Although multiple molecular mechanisms contribute 
to the development of obesity-related complications, recent data (Ferrante, 2007) suggest 
that inflammation, especially that involving monocytes and macrophages, is a central axis in 
the pathophysiology of many obesity-related disorders. Obesity is accompanied by 
infiltration and activation of macrophages in adipose tissue, leading to the chronic 
inflammation of adipose tissue. Adipose tissue has been reported to be an important organ 
of obesity-induced inflammation as determined by measurement of its expressions of pro-
inflammatory molecules (Hotamisligil et al., 1993). Obesity induces phenotypic changes in 
adipocytes, such as hypertrophy, and also induces an inflammatory response in adipocytes 
in an autocrine or paracrine fashion, resulting in impaired adipocyte function, including 
insulin signaling (Hotamisligil et al., 1996).  
Several studies have reported that overexpression of MCP-1 causes macrophage recruitment 
in adipose tissue and insulin resistance (Kamei et al., 2006; Kanda et al., 2006). Adipocytes 
express CCR2, the primary receptor for MCP-1, which causes the expressions of 
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inflammatory genes and impaired uptake of insulin-dependent glucose (Charo & Ransohoff, 
2006). Obese mice with a CCR2 deficiency have shown improved insulin resistance, 
attenuated hepatic steatosis, increased adiponectin expression, and reduced macrophage 
content in adipose tissue when the mice were induced into obesity by a high-fat diet 
(Weisberg et al., 2006). Several CCR2 antagonists also resulted in decreased macrophage 
accumulation in adipose tissue with an accompanying improvement in insulin resistance 
(Kang et al., 2010b; Tamura et al., 2008). These results propose the possibility of an 
expanded role of the CCR2 genotype in adipose and hepatic tissues against insulin 
resistance in metabolic syndrome. Therefore, the MCP-1⁄CCR2 pathway might have an 
important role in insulin resistance with macrophage infiltration into adipose tissue, leading 
to systemic inflammatory and metabolic consequences.  
Considering that inflammation in both adipose tissue and the kidney has an important role 
in insulin resistance and metabolic syndrome, common mechanisms between adipose tissue 
and the kidney should be identified. There may be cross-talk between adipose tissue and the 
kidney with obesity-induced inflammatory injury in metabolic syndrome, particularly in 
diabetic nephropathy. We performed mutual epididymal fat transplantation between 
diabetic and non-diabetic animals to support this hypothesis (Kim et al., 2010). We observed 
that diabetic db/db mice who received epididymal fat from normal db/m mice showed a 
significant decrease in urinary albumin excretion. In addition, there was significant 
improvement in renal pathologic changes, including decreases in TGF-β1, type IV collagen 
and PAI-1 protein expressions. The beneficial effect of non-diabetic epididymal fat 
transposition into diabetic animals supports the possibility of this same type of cross-talk in 
type 2 diabetic nephropathy. Functional and phenotypic changes in adipose tissue in obesity 
might have an impact on renal function through the various mechanisms of metabolic and 
hormonal effects, such as the MCP-1/CCR2 pathway and those of numerous 
adipocytokines. 
2.7 Role of the Vitamin D Receptor (VDR) 
Vitamin D deficiency is known to be related to cardiovascular disease and chronic kidney 
disease. Vitamin D improves albuminuria and the progression of renal injury independent 
of its classic actions (de Zeeuw et al., 2010; Deb et al., 2010; Kang et al., 2010). These animal 
studies provide rationale for treatment with the vitamin D receptor (VDR) agonist, 
paricalcitol, in the improvement of type 2 diabetic nephropathy and lipid metabolism. In the 
present study, there were no differences in the basal characteristics of body weight, fasting 
plasma glucose, HbA1c, glucose tolerance test, insulin tolerance test, serum creatinine level, 
or systolic and diastolic blood pressure. However, paricalcitol improved cardiac left 
ventricular mass index and urinary albumin excretion. Moreover, paricalcitol-treated 
diabetic mice showed improved plasma lipid profiles of total cholesterol, triglycerides and 
LDL cholesterol. Interestingly, cholesterol and triglyceride contents in kidney tissue were 
dramatically decreased by paricalcitol, and a similar result was observed in fat and liver 
tissues. In addition, plasma and urinary 8-isoprostane levels were markedly inhibited by 
paricalcitol treatment. Tissue lipid peroxidase (LPO) levels in kidney, fat and liver tissues 
were significantly improved. Paricalcitol suppressed the pro-inflammatory molecular 
synthesis and improved the morphological changes in renal glomerulosclerosis, hepatic 
steatosis and adipose phenotypic change of diabetic mice. The in vitro experiment with 
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cultured VDR-siRNA mesangial cells revealed changes in gene expression and protein 
synthesis of the enzymes related to the lipid metabolism of fatty acid synthase (FAS), 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-Co AR; inducing cholesterol 
synthesis) and sterol-regulatory element-binding protein-1c (SREBP-1c; inducing cholesterol 
synthesis). Paricalcitol may have a protective effect on diabetic nephropathy through an 
improvement of systemic and tissue lipid metabolism and an anti-oxidative effect. 
3. Conclusions 
The role of the kidney is not only as a target organ during the development of obesity and 
metabolic syndrome, but also as a regulatory organ that cross-talks with adipose tissue. A 
large body of evidence has demonstrated that various adipocytokines, RAAS and VDR of 
the kidney and adipose tissue are associated with one another; alterations of these 
substances can lead to many complications of metabolic syndrome that develop from 
obesity-induced inflammation. Eventually, the improvement of insulin resistance through 
an anti-inflammatory effect on adipose tissue could result in the improvement of diabetic 
nephropathy, which decreases cardiovascular complications in metabolic syndrome. A 
better understanding of adipose tissue biology will help researchers develop a new 
therapeutic strategy to manage metabolic syndrome, including diabetic vascular 
complications. Future studies should focus on the aforementioned potential targets to 
improve insulin resistance as well as diabetic nephropathy. 
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